Recent therapeutic advances, in particular the use of anti-tumour necrosis factor (anti-TNF)
agents, have revived interest in the seronegative spondyloarthropathies (SpA), a group of …

Spondylarthropathies revolve around the strongest known contributing factor, HLA-B27.
However, the role of HLA-B27 remains unclear. Its subtypes are reported here in the …

The aim of this study was to characterize the socioeconomic features, as well as disease
activity and functional status, treatment use, and quality of life in a cohort of Egyptian …

Objectives. For effective health care provision, knowledge of disease prevalence is
paramount. There has been no systematic endeavour to establish continent-based AS …

In the past decade, major progress has been made in the recognition, classification and
treatment of spondyloarthritis (SpA). Classification criteria have been developed for axial …

The prevalence of spondyloarthropathy (SpA) in Chinese Indonesians is much higher than
in native Indonesians. This is due to HLA-B27 subtype differences. In the present study we …

Objective To develop a French version of the Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) and to determine its metric properties in patients with all forms of …

Ankylosing spondylitis (AS) and the related spondyloarthritis (SpA) have become an
extremely productive field in immunogenetic research over the last several years, justifying …

W HEN in 1973 Brewerton et al'and Schlosstein et al2 reported the association between
HLA-B27 and ankylosing spondylitis (AS), it seemed possible that the pathogenesis of AS …

Early diagnosis of spondyloarthritis (SpA) is essential as anti-tumor necrosis factor therapy
can achieve significant symptomatic relief and control of disease activity. This study aims to …